Sanofi and Evotec launch drug discovery PPP
Evotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2191 entries already.
Entries by Thomas Gabrielczyk
Roche providing improved anti-Her2 bispecific antibody
Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
A new treatment paradigm
Medigene is developing the next generation of effective TCR cell therapies aimed at establishing better control over cancer at reasonable production cost.
Experts discuss process intensification
Roughly 150 life science professionals met at the 5th Biotech Days to discuss the latest progress in bioprocess intensification.
Forbion closes Life Sciences VC Fund at €360m
Life Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m.
BIOSPAIN expanding
Matured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in Spain.
Minoryx bags €21.3m Series B financing
Barcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M.
PD-1+ T cells trigger pulmonary fibrosis
A team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
Roche’s Tecentriq prolongs OS in SCLC
Cancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the company’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by only two months as first-line treatment for patients with the rare lung cancer SCLC.
CRISPR-gene drive safely kills mosquitos
A new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.